By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International, Inc. (NASDAQ:DYAI) and VTT have developed a production platform that boasts higher efficiency and lower cost based on Dyadic’s C1, Thermothelomyces heterothallica , expression platform, and are now developing a production method for a SARS-CoV-2 vaccine as discussed in an article on the VTT research
